Key Highlights

  • Paradigm has drawn down the remaining US$2 million balance of Tranche 4 under its US$27 million Convertible Note Facility with Obsidian Global Partners, LLC.
  • The company's global Phase 3 trial (PARA_OA_012) evaluating injectable pentosan polysulfate sodium has completed enrolment at 538 participants, ahead of the original target of 466.
  • Approximately US$5 million remains available under the facility following completion of the Tranche 4 drawdown.
  • PAR shares declined 7.02% to A$0.26 on the day the announcement was released.

Facility Drawdown Details

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) advised the market on 11 September 2026 that it has drawn down the remaining balance of Tranche 4 under its Convertible Note Facility with Obsidian Global Partners, LLC. The tranche, valued at US$2 million (approximately A$2.8 million), follows an initial US$3 million portion of Tranche 4 that was drawn and announced on 13 July 2026. The overall facility with Obsidian Global Partners is sized at US$27 million (approximately A$41.2 million).

The drawdown forms part of a structured funding arrangement that has been accessed in stages. Tranche 1, Tranche 2 and Tranche 3 were drawn down and announced on 1 July 2025, 17 November 2025 and 18 February 2026, respectively. With Tranche 4 now complete, the company reports that approximately US$5 million (approximately A$6.9 million) remains available under the facility for future use.

Phase 3 Trial Status

The additional Capital is directed toward supporting Paradigm's global Phase 3 clinical trial, PARA_OA_012, which is evaluating injectable pentosan polysulfate sodium (iPPS) as a treatment for knee osteoarthritis. The company confirmed that enrolment in the trial has been completed at 538 participants, exceeding the original target of 466 participants set for the study.

With enrolment finalised, the company's stated focus has shifted to patient treatment, follow-up assessments and data collection across its clinical site network, which spans the United States, Australia, Hong Kong and Moldova. The funds drawn under Tranche 4 are earmarked for ongoing clinical operations, database management and regulatory activities as the trial progresses toward its planned interim analysis and subsequent top-line primary endpoint readout.

Funding Position

Paradigm stated that it remains funded through the planned interim analysis and top-line primary endpoint readout for the trial. The company described its approach to capital management as directed toward activities that support clinical delivery, with the remaining US$5 million balance under the facility providing additional flexibility to support ongoing Phase 3 execution and broader commercial readiness activities as the program advances.

Conclusion

The completion of the Tranche 4 drawdown provides Paradigm Biopharmaceuticals with additional Working Capital as its Phase 3 trial for iPPS in knee osteoarthritis moves into its next operational phase following the completion of patient enrolment. With approximately US$5 million still available under the Obsidian Global Partners facility and enrolment having exceeded its original target, the company's near-term focus rests on patient follow-up, data collection and progression toward the planned interim analysis and top-line readout across its site network in the United States, Australia, Hong Kong and Moldova.